C-labeled glucose (ARC-0122G), 2-14 C-malonyl-CoA (2239094, Perkin Elmer), and palmitic acid [1, 14C] sodium salt (ARC 4007) were used. Matrigel (354234, Corning) was used for in vivo cell injection.
Supplementary Figures
Figs. S1 to S14
Other supplementary materials for this manuscript include the following: Datasets S1A to S1N for 6 days, without medium replacement. Cells and conditioned medium were collected and cell growth was assessed by counting the number of viable cells using the Vi Cell XR analyzer (Beckman Coulter) based on trypan blue exclusion method. For Enza and IPI-9119 combination experiments, cells were pretreated with IPI-9119 (0.1 uM) or DMSO for 6 days, then were replated at 200,000/well for 40 hr in the presence of IPI-9119 or DMSO. At end of 40 hr, the medium was changed and single or combinatorial treatments were added. Enza (20 uM) was re-added after 3 days.
Clonogenic assay
22Rv1 (500 cells) and C4-2 (250 cells) were plated in 6-well plates. After 40 hrs, cells were treated with DMSO, 0.1 or 0.5 µM IPI-9119 in 10% FBS containing medium for 3 weeks. Medium was replaced every 7 days. At the end of the 3 weeks, medium was gently removed, colonies were fixed in fixing solution (10 % acid acetic, 10 % ethanol) for 1 hr at RT and stained with 0.1% crystal violet. Wells were carefully washed to remove excess of staining and dried over-night. Pictures were taken using an Epson scanner. Clonogenic ability was quantified by measuring the absorbance (OD= 595) following dye extraction using 10% acid acetic and agitation for 2 hrs at RT.
Cell cycle studies
The percentage of cells in sub-G1, G1, S, and G2-M phase of the cell cycle was analyzed with a BD LSR II flow cytometer (Becton Dickinson), following PI and BrDU staining, using a standard protocol.
Briefly, after incubation with BrDU (10 uM, 2 hrs), cells were fixed with ethanol. Cells were incubated with anti BrDu-FITC (BD bioscience) antibody for 20 min, followed by PI (10 ug/ml) labeling (30 min), and FACS analysis. Flow cytometry data were analyzed using the software package FlowJo (version 9.6.4). Cyclins levels were analyzed by immunoblotting. Apoptosis was analyzed by detection of cleaved Parp (c-Parp) in cell lysates and by measuring membrane redistribution of phosphatidylserine using Apo Alert Annexin V-FITC/PI apoptosis kit (Clontech), as described by the manufacturer.
Immunoblotting
Cells were lysed in 1% NP-40 buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40) or RIPA buffer with the addition of phosphatases and protease inhibitor cocktail (Sigma and Roche). For tumor xenograft samples, tissues were homogenized in 1% NP-40 buffer using Tissue-Tearor homogenizer (BioSpec Products). Protein quantification was performed using Bradford protein assay (Bio-Rad). Equal amounts of protein were resolved on precast tris-glycine SDS-polyacrylamide gels (Invitrogen). Bands were quantified by densitometry using the Quantity One software (version 4.6.1, Bio-Rad). Results were normalized to β-actin or vinculin and expressed in arbitrary units. Nuclear and cytoplasmic proteins were extracted using NE-PER Nuclear and Cytoplasmic Extraction Kit (#78833, Thermo Fisher). Protein fractions were quantified and analyzed by immunoblotting, using lysine-specific demethylase 1 (LSD-1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as nuclear and cytoplasmic markers, respectively. Primary antibodies used in this study were the following: FASN (BD transduction laboratories, #610962; CST#3180); b-actin (anti-mouse Sigma, A5316; anti-rabbit CST#4967S); c-Parp (CST# 9541S); cyclin A2 (CST#4656S); cyclin D1 (CST#2978S); Vinculin (antimouse Sigma, V9131); AR (Abcam #ab108341, which recognizes both AR-FL and AR-V7); AR-V7 specific (RevMAb Biosciences #31-1109-00); c-MYC (Abcam #ab32072); PSA (Dako, A0562); GAPDH (CST#2118S); LSD-1 (CST#4064S); eiF2a (CST#5324S); p-eIF2a (CST#9721S), eIF4B Lipids were extracted with petroleum ether. Radioactivity was measured by scintillation counting using the b-counter (Perkin Elmer Tri-carb 3180TR/SL). Counts per minute (cpm) in 1 ml of extract were measured and normalized to protein content.
FASN activity using the purified human FASN protein was performed as following: human FASN protein was purified from SKBR3 cells using procedures modified from those described in (3) . SKBR3 cells were obtained from ATCC and grown in DMEM high glucose medium supplemented with 10% FBS, 1 ug/mL bovine pancreas insulin, 100 U/mL penicillin and 100 ug/mL streptomycin. Cells were trypsinized and washed three times with PBS, frozen in liquid N 2 , and stored at -80°C. Frozen cells were thawed on ice and resuspended in lysis buffer (25 mM Tris-HCl, pH 7.0, 15 mM NaCl, 1 mM EDTA, and 1 mM DTT) with protease inhibitors. Cells were lysed by sonication, and the cell debris were removed by centrifugation at 20,000 rpm for 30 min. Neutralized saturated ammonium sulfate solution was added (final concentration of 35%) to the supernatant. Solution was left on ice for 1 hr, and the precipitated proteins were harvested by centrifugation at 20,000 rpm for 30 min. Proteins were re-dissolved in lysis buffer without NaCl and loaded on a mono Q column. Bound proteins were eluted with a linear gradient of NaCl in lysis buffer. Each fraction was analyzed by SDS-PAGE and FASN NADPH consumption assay. The fractions containing FASN were pooled and concentrated. Glycerol was added to 20%, and the protein was frozen in liquid N 2 and stored at -80°C, until use. FASN activity using the purified protein was measured using a FASN Scintillation Proximity Flashplate Assay, as described in (4 
C-glucose incorporation into lipids
LNCaP cells were plated (4×10 5 ) in 60 mm dish and treated with IPI-9119 for 72 hrs. Twenty-four hrs before harvesting, cells were incubated with 1uCi of 14 C-labeled glucose. Medium was removed, cells washed and collected in a glass vial. A mixture of methanol: chloroform: water (2: 1: 0.5) was added and the lipids were extracted as described by Bligh & Dyer (5) . 14 C-glucose incorporation into cellular lipids was quantitated by scintillation counting and normalized to mean protein content. Five biological replicates were used (3 for lipid extraction and 2 for protein normalization).
FAO analysis
LNCaP cells were seeded in 12-well plates for 48 hrs. 7 biological replicates were used for the experiments (4 for FA oxidation measurement, 3 for protein normalization). Cells were treated for 6 days with IPI-9119 or DMSO and 2.5 hrs before harvesting 14 C-palmitate-complexed with BSA was added to the cell medium. At the end of the incubation period, 100 ul of 70% perchloric acid were added to each well, firmly covered with a piece of Wathman filter paper, previously saturated with phenylethylamine.
Plates were firmly covered with saran wrap and rocked for 2.5-3 hrs at RT. FA oxidation was measured as the production of 14 C-CO 2 trapped in the Wathman filter paper. Radioactivity was measured by scintillation counting and normalized to mean protein content.
Oil Red O staining
LNCaP cells were treated with IPI-9119 or DMSO for 6 days, washed carefully with PBS and fixed for 30 min with fresh 10% neutral buffered formalin. Six replicates/condition were used (three for Oil Red O staining, three for protein normalization). After washing with PBS and dry the dish, cells were incubated for 30 min with Oil red O in 0.5% isopropanol solution (O1391, Sigma). Dishes were washed to remove the excess of staining. Dishes were dried and pictures were taken using an Olympus CK40 microscope.
For quantitative analysis, cell-bound Oil red O was extracted in 1 ml of 100% isopropanol in agitation for 1 hr and absorbance was measured (OD= 510 nm). Absorbance value from similarly treated plates but without cells was used as blank and subtracted from the experimental values.
Cholesterol measurement
Cholesterol levels in murine tissue were measured using the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific), as per manufacturer's instruction.
RNA extraction and RT-qPCR
Total RNA was extracted with the RNeasy Plus MiniKit (Qiagen). Two micrograms of RNA were retrotranscribed with a High-Capacity cDNA Reverse Transcription Kit (Applied biosystems), as described by the manufacturer. For single gene mRNA analysis, 10 ng of cDNA were used. The relative gene expression was determined by the delta-delta Ct method (6) 
Luciferase assay
LNCaP cells were seeded at 2x10 4 cells/well in 24-well plates and treated with IPI-9119 or DMSO the following day. After incubation for 72 hrs, each well was transfected with 375ng of PSA-Luc and 125ng of SV40-REN constructs, using Fugene HD as manufacturer's recommendations. Twenty-four hrs posttransfection, cells were treated for additional 24 hrs with 10 µM Enza or vehicle (0.1% v/v ethanol).
Cells were harvested in 1x passive lysis buffer provided in a Dual Luciferase Assay Kit (Promega).
Activities of the firefly and Renilla luciferase reporters were assayed by Dual Luciferase Assay, as per manufacturer's recommendations. Data were normalized by dividing firefly luciferase by Renilla luciferase activity.
RNA-sequencing and data analysis
RNA Quality Control (QC): RNA quality was assessed by running all samples on the Agilent Bioanalyzer, using the RNA 6000 Nano assay. Any sample with a RNA integrative number (RIN) value greater than 6.0 passed QC and was used for library preparation. The concentration of total RNA was determined using the RNA High-Sensitivity Qubit assay. The concentration of dsDNA was also measured using the DNA High-Sensitivity Qubit assay to ensure that less than 10% DNA contamination was present in the samples before library preparation.
Library preparation: mRNA was isolated from 100 ng of total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module, which was then reverse transcribed and library prepped using the NEBNext Data alignment: Fastq files were aligned to the human 19 genome using STAR aligner with default parameters (version 2.3.1z4), producing BAM files as output, which were passed through several processing steps. The *.sort.primary.bam files, which retain only the primary alignments, were used for further analysis.
RNA-Sequencing (RNA-Seq) QC: RNA-Seq quality metrics were produced using the Broad Institute's RNA-SeQC tool (7) (http://www.broadinstitute.org/cancer/cga/rna-seqc).
Read quantification and normalization: Reads and differential expression analysis were treated at the gene level, as opposed to inference about specific transcript abundance. The feature Counts software, which produces integer counts for all genes, was used (8) . For read normalization, DESeq normalization software, as part of the DESeq package (7), was used.
Differential expression testing: For differential expression testing, DESeq software was used, as previously described (9) . The output files were named according to the contrast performed and described in Table S1 . Normalized_count_matrix.sort.primary.counts were used for heatmap generation.
Gene set enrichment analysis (GSEA)
GSEA (10) Pathways were considered significantly enriched or depleted at p<0.05 and FDR<0.15.
Metabolic profiling
Sample preparation and metabolomics techniques: Dry pellet of 5x10 6 chromatographically optimized for more hydrophilic compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm, 1.7 µm) using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic positive ion conditions, however it was chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the same afore mentioned C18 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was operated at an overall higher organic content. Another aliquot was analyzed using basic negative ion optimized conditions with a separate dedicated C18 column. The basic extracts were gradient eluted from the column using methanol and water, however with 6.5mM Ammonium Bicarbonate at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10mM
Ammonium Formate, pH 10.8. The MS analysis alternated between MS and data-dependent MS n scans using dynamic exclusion. The scan range varied slighted between methods but covered 70-1000 m/z. QA/QC: Several types of controls were analysed together with the experimental samples: 1) a pooled matrix sample was generated by taking a small volume of each experimental sample (or alternatively, a pool of well-characterized human plasma) and served as a technical replicate throughout the data set; 2)
extracted water samples served as process blanks; 3) a cocktail of QC standards that were carefully chosen to not interfere with the measurement of endogenous compounds were spiked into every analysed sample to monitor instrument performance; and aided in chromatographic alignment. Instrument variability was also evaluated during the entire procedure. Experimental samples were randomized across the platform, and run with QC samples spaced evenly among the injections.
Data extraction and compound identification: Raw data were extracted, peak-identified, and QCprocessed, using Metabolon's hardware and software, Compounds were identified by comparison to library entries of purified standards, or to recurrent unknown entities. Metabolon maintains a library based on authenticated standards that contain the retention time/index (RI), m/z, and chromatographic data (including MS/MS spectral data) for all molecules present in the library. More than 3300 commercially available purified standard compounds have been acquired and registered into the Metabolon laboratory management information systems, for distribution to both the LC-MS and GC-MS platforms for determination of their analytical characteristics. The QC and the curation processes were designed to ensure accurate and consistent identification of true chemical entities, and to remove those entities that represent system artifacts, mis-assignments, and background noise.
Metabolite quantification and data pre-processing: Peaks were quantified using area-under-the-curve.
Data were normalized, to correct variations that resulted from differences in the inter-day tuning of the instruments. Essentially, each compound was corrected in run-day blocks, by registering the medians to equal one, and normalizing each data point proportionately. Further information is provided in (11, 12) .
Lipidomics
As described in (13) immunofluorescence staining was performed on the Leica Bond Rx automated immunostainer.
Positivity at the cell level was defined in a semi-automatic fashion for each marker (see below).
Metastatic sites were defined as positive if at least 5% of tumor cells were scored positive. Each patient was classified as positive for each of the investigated markers (i.e., FASN, AR-FL, and AR-V7) if at least one of his metastatic sites was scored positive for that protein. algorithm was then applied to all the core images within the TMA batch. All segmented images from the batch were reviewed by a pathologist and manually edited for accuracy before the final segmentation data were generated. TMA cores with severe tissue folding, major staining artefacts or no viable tumour were excluded from the analysis.
TSA-plus Fluorescence Immunohistochemistry

Intensity scoring per metastatic site
Signal units were expressed as fluorescent count normalized to exposure time, as given by InForm software. Based on a combined approach that considers background noise, bona-fide negative signal (e.g., neuroendocrine cases), and visually-inspected weak specific signal, thresholds for positivity were established at the cell level for each fluorophore. Signal thresholds (expressed as total weighted mean)
were found to be: 0.14 for FASN (cytoplasm); 3.07 for AR-V7 (nucleus); 3.84 for AR-FL (nucleus).
After merging the information from the replicate cores, each metastatic site was defined as positive if the rate of positive-scored cells exceeded 5% of the segmented tumour area.
Statistical analyses
Mean comparison in IPI-9119 treated group/groups vs vehicle group was performed using Student t-test or one-way ANOVA followed by Tukey's post-hoc test to correct for multiple comparisons. When two independent variables were tested, two-way ANOVA was used, followed by Sidak's post-hoc test to correct for multiple comparisons. Non-parametric Mann Whitney test was used to compare tumor volume at the end of the treatment (IPI-9119 or vehicle) period. GraphPad Prism 7.0 was used for these statistical analyses and graphical representation. For RNA-seq analyses, differential expression analysis was performed using DESeq software. Details are provided in supplementary Material and Methods (RNA-seq section). GSEA and MSEA were performed using the GSEA algorithm (10) . Details for these analyses are provided in supplementary Material and Methods. Probabilistic quotient normalization method was used to normalize both metabolomics and lipidomics data (14) . For metabolomics analysis, metabolites with more than 70% of missing values in each cell line set were removed from analyses to allow the inclusion of those specifically reduced under the detectability threshold in IPI-9119 treated samples. Then, the number of missing metabolites in the 5 replicates of each condition (i.e., drug and cell line) was counted. When the number was higher than 3, missing values were imputed with zero;
otherwise, missing values were imputed using the k-nearest neighbor (kNN) algorithm (15) , with k=3.
The kNN imputation is an efficient method to fill in missing data by a value obtained from related cases in the whole set of records. By limiting the kNN imputation to the metabolites with at least 2 values out of 5/condition, imputation using the information from different conditions (e.g., treated and non-treated) was avoided. Principal component analysis (PCA) was used to visualize the metabolomic data. Data were log-transformed, mean-centered and scaled to unit variance before PCA (Qlucore Omics Explorer version 3.1). Normalized, imputed data were used for univariate analyses and box-plot representations of key metabolites. Student t-test was used to identify significantly altered metabolites for each drug concentration. In both RNA-seq, metabolomics, lipidomics analyses, multiple comparisons were corrected using false discovery rate (FDR). Differences were considered significant with p<0.05 and, if multiple comparisons were done, FDR <0.05. For GSEA and MSEA, an FDR threshold of 0.15 was used. RNA-seq and metabolomics/lipidomics analyses were done using R software. Heatmaps were ordered according to hierarchical clustering (Ward linkage) on the basis of the KODAMA dissimilarity matrix, implemented in R package KODAMA (16) . Representative images of FASN co-expression with AR-FL and AR-V7 (20X) in liver metastases: Bright field (a), FASN/AR-FL staining (b), FASN/ AR-V7 staining in AR-V7-negative liver metastasis from a mCRPC Enza/Abi-naïve patient (c); Bright field (d), FASN/AR-FL staining (e), FASN/ AR-V7 staining in AR-V7-positive liver metastasis from a mCRPC Enza/Abi-naïve patient (f); Bright field (g), FASN/AR-FL staining (h), FASN/AR-V7 staining in AR-V7-positive liver metastasis from a mCRPC Enza/Abi-treated patient (i).
